NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » Company watch » TOP 50 Pharmas » GlaxoSmithKline  1  2  » 
found files: 22
GlaxoSmithKline »03/05/2007 [Company watch]
China recognises GSK for busting fake drugs racket

Undercover agents employed by GlaxoSmithKline (GSK) posed as traders in fake medicines to help to close down a global pharmaceutical counterfeiting racket based in China...   more»

GlaxoSmithKline »23/05/2007 [Company watch]
Glaxo to unveil major China drug research centre

LONDON, May 23 (Reuters) - GlaxoSmithKline Plc (GSK.L: Quote, Profile , Research) is set to unveil plans for major research and development centre in China, joining a growing number of pharmaceutical companies tapping into the country's skillbase in life sciences. Research head Moncef Slaoui told the annual meeting of Europe's biggest drugmaker on Wednesday that an announcement on the investment in a fully integrated research and development facility was imminent....   more»

GlaxoSmithKline »24/05/2007 [Company watch]
GlaxoSmithKline launches Chinese R&D centre with appointment of head in Shanghai

Jingwu Zang to lead work on neurogenerative diseases GlaxoSmithKline (GSK) today announces the appointment of Jingwu Zang to head a new GSK research and development centre in Shanghai, China. His appointment, as Senior Vice President, will be effective in June....   more»

GlaxoSmithKline »29/05/2007 [Company watch]
GlaxoSmithKline set up a drug research centre in China.

GlaxoSmithKline (GSK) is the latest pharma heavyweight to set up a drug research centre in China....   more»

»03/07/2007 [Company watch]
GSK to Spend US$40 Million in R&D in China

GlaxoSmithKline (GSK) said yesterday that it will spend US$40 million this year to start a research facility in Shanghai that will grow into one of its largest research centers globally....   more»

GlaxoSmithKline »03/08/2007 [Company watch]
Sinovac Enters Exclusive Promotion Service Agreement with GlaxoSmithKline (China) Investment Co., Lt

Sinovac Biotech Ltd. , a leading provider of biopharmaceutical products in China, today announced it has entered into an Exclusive Promotion Service Agreement with GlaxoSmithKline (China) Investment Co., Ltd. (or GSK China). GSK China and Sinovac will market and promote Anflu(R), a seasonal influenza vaccine developed and manufactured by Sinovac....   more»

GlaxoSmithKline »13/12/2007 [Company watch]
GSK says will spend $100m in China R&D

Hong Kong, Dec 13, 2007: British pharma giant GlaxoSmithKline (GSK) has said it will invest $100 million by 2008 end to start a neuroscience research center in Shanghai. According to a UK business paper the Chinese center will become an important base for GSK to develop global drug. GSK’s Chairman of R&D, Moncef Slaoui told the paper that the Shanghai center will be a one stop shop doing research on all neurodegenerative diseases such as Alzheimer's, Parkinson's disease and multiple sclerosis. The paper quoted him as saying, "For us, China is not about outsourcing and cheap labor. We don't want to give them the crumbs. It's about different science. We will link our fate to their fate. Within five to ten years we will be moving from 'made in China' to discovered in China." Increasingly global pharma companies are looking at China and India both as ready market and a place to do high end research due to their huge population and young scientists and professionals. GSK zeroed in on China as it was looking at the next seedbed for future discoveries. Slaoui said, "qualitatively and numerically, China came out on top, especially in oncology and neurology.”...   more»

GlaxoSmithKline »03/05/2008 [Company watch]
GSK reorganiseis to focus on emerging markets

GlaxoSmithKline (NYSE: GSK) has reorganized its corporate structure to put an increased focus on emerging markets. A new management group was given the charge of increasing business in the Emerging Markets, defined as China, Russia, Brazil, India and the Middle East. Even though the countries are not closely linked geographically, GSK believes the structure of the pharmaceutical markets in each nation is very similar, allowing for a unified strategy. The move was taken because of the growth for pharmaceuticals expected in these countries....   more»

GlaxoSmithKline »11/07/2008 [Company watch]
GlaxoSmithKline to Double China R&D Staff

GlaxoSmithKline Plc announced that it will increase its China-based research and development staff to 350 people in the next few years. Currently, the company has 170 employees on its R&D roster at its Shanghai facility. That number will move up to 200 by the end of this year, and it will jump to 350 within a year or so. At that point, staffing will level off for three or four years while new facilities are built. The comments were made at the ChinaBio Investor Forum held in Shanghai by Carol Zhu, who is head of operation management and alliances in the R&D department for GSK. The ChinaBio Investor Forum was organized by the ChinaBio Accelerator, which is a sister organization to ChinaBio Today.These increases are lower than the numbers projected at the end of 2007. In December 2007, GSK said it expected to have invested $100 million in its Shanghai facility by the end of 2008 and have 1000 staff members employed there by 2010. When it was started, GSK’ Shanghai R&D center had the stated goal of focusing on neurodegenerative diseases such as multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease. The Shanghai center was tasked with eventually directing GSK’s R&D activities in this therapeutic area, coordinating with other GSK centers around the world and research institutions in China and globally. The Shanghai center began operations in the summer of 2007....   more»

GlaxoSmithKline »24/07/2008 [Company watch]
GlaxoGSK Makes Generics Deal to Penetrate Emerging Markets

SmithKline has made a strategic alliance with Aspen PharmaCare, a South African generic drug company, as a means of penetrating emerging markets such as China. GSK noted that 40% of the expected growth in pharmaceutical markets worldwide will be in emerging countries. GSK did not pay an upfront fee in its arrangement with Aspen, but will make a small upfront payment for each product that it elects to register and then pay royalties, as the big pharma extends the marketing range of Aspen’s products into new territories....   more»

GlaxoSmithKline »23/07/2008 [Company watch]
GSK sets out new strategic priorities

In a presentation to investors today, Andrew Witty, CEO GlaxoSmithKline, set out three new strategic priorities that aim to increase growth, reduce risk and improve GSK’s long-term financial performance. Outlining the context for the priorities Witty said: “In the next few years the pharmaceutical industry will face immense challenges as an unprecedented number of products lose patent protection. This will be set against a backdrop of payors searching for ever more cost-effective healthcare and escalating patient demand for new and better medicines.” “Our aspiration to improve the lives of patients and consumers is intrinsically aligned to the requirements of our shareholders,” he said. At the same time though, he stated that the industry is currently perceived in financial terms as being one of ‘higher risk’ and ‘lower growth’ and that companies must work harder to demonstrate greater return from investments in R&D. “These new strategic priorities will evolve GSK into a company that has a balanced group of healthcare businesses and a lower overall risk profile,” said Witty. “They also point to a more disciplined allocation of capital across all our different business areas...   more»

GlaxoSmithKline »13/11/2008 [Company watch]
GSK keen on China for R&D

China plays a key role in the global strategy and development of GlaxoSmithKline....   more»

GlaxoSmithKline »24/11/2008 [Company watch]
GSK in a JV to develop flu vaccines, targets China

Pharmaceutical major, GlaxoSmithKline (GSK) has signed a cooperation agreement with Chinese company, Shenzhen Neptunus Interlong Bio-Technique (NIBT) to form a Joint Venture (JV) between the companies....   more»

GlaxoSmithKline »01/12/2008 [Company watch]
GSK and Neptunus sign cooperation agreement to form joint venture

GlaxoSmithKline (GSK) announced that it has signed an exclusive Cooperation Agreement with Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. (NIBT) as a preliminary step in forming a Joint Venture (JV) between the two companies....   more»

GlaxoSmithKline »19/12/2008 [Company watch]
Domestic version of GSK anti-influenza treatment cleared for clinical trials

he active pharmaceutical ingredient (API) and inhaler capsule of Zanamivir, an antiviral/anti-influenza neuraminidase inhibitor, recently passed pre-clinical evaluation by the National Center for Drug Evaluation and was approved to enter clinical trials. The drug was jointly submitted by the Shanghai Institute of Materia Medica of Chinese Academy of Sciences(CAS), Nanjing Simcere Dongyuan Pharmaceutical, and Nanjing Yifang R&D Corporation. The originator of Zanamivir is GSK, which markets the drug under the brand name Relenza....   more»

GlaxoSmithKline »13/04/2009 [Company watch]
GSK to invest more in new drug development

Drug maker GlaxoSmithKline (GSK) expects to maintain its fast pace of growth in China with additional investments for development of new medicines and vaccines...   more»

GlaxoSmithKline »02/05/2009 [Company watch]
GSK sees opportunity in China

GSK plans to launch two new products in China this year, including Boostrix (a diphtheria, tetanus and pertussis vaccine for adolescents) and DTPa-Hib (a combination vaccine for diphtheria, tetanus, pertussis and haemophilus influenza type B diseases), according to Jean Stephenne, the company president and general manager....   more»

GlaxoSmithKline »29/06/2009 [Company watch]
GSK says Asia Pacific sales could double in 5 yrs

(Reuters) - British drugmaker GlaxoSmithKline said its Asia-Pacific sales could double in five years as growing prosperity boosts demand for better healthcare and as it cuts prices in some Asian countries....   more»

GlaxoSmithKline »24/07/2009 [Company watch]
GSK to Distribute Dr. Reddys Generics in Emerging Markets

GlaxoSmithKline has partnered up with Dr. Reddys Laboratories in a deal that will allow GSK to sell Dr. Reddys generic pharmaceutical products in emerging markets. The targeted countries include China, though Dr. Reddys home market of India is excluded....   more»

»12/10/2009 [Company watch]
GlaxoSmithKline Forms Vaccine JV for the China Market

GlaxoSmithKline has formed a JV with Jiangsu Walvax Biotech Company to develop and manufacture pediatric vaccines for the China market. Initially, the JV will be funded with $65.6 million of capital, of which $32 million (65%) will come from GSK. GSK has also agreed to provide an additional $11.6 million in 2015. The agreement contains provisions allowing both companies to increase their stakes in the future....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.